GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Perrigo Company PRGO · USD

Health Care · US listing · 🇺🇸 United States

Compare

16.95

+6.94%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Perrigo Company annual report

Filed with the US Securities and Exchange Commission

10-K

The latest annual report covers the year to 31 Dec 2025, filed on 26 Feb 2026.

Read the 10-K on SEC.gov ↗

Five-year highlights

In USD.

FY2025FY2024FY2023FY2022FY2021
Revenue$4.25bn$4.37bn$4.66bn$4.45bn$4.14bn
Operating income$343.3m$112.9m$151.9m$78.9m$410.4m
Net income−$1.43bn−$171.8m−$12.7m−$140.6m−$68.9m
Free cash flow$145.1m$244.6m$303.8m$210.9m$4.2m
Total assets$8.54bn$9.65bn$10.81bn$11.02bn$10.43bn
Shareholders' equity$2.94bn$4.32bn$4.77bn$4.84bn$5.15bn

Revenue by business

Year to 31 Dec 2025

  • Nutrition $408.5m · 9.6%
  • Skin Care $407.7m · 9.6%
  • Upper Respiratory $288.2m · 6.8%
  • Contract Manufacturing $270.9m · 6.4%
  • Pain and Sleep-Aids $235.4m · 5.5%
  • Healthy Lifestyle $231.5m · 5.4%
  • Vitamins, Minerals, and Supplements ("VMS") $161.2m · 3.8%
  • Women's Health $143.5m · 3.4%
  • Oral Care $97.5m · 2.3%
  • Other CSCI $62.4m · 1.5%

Revenue by region

Year to 31 Dec 2025

  • United States $2.54bn · 59.7%
  • Europe $1.62bn · 38.0%
  • All Other Countries $96.7m · 2.3%
  • Ireland $42.1m · 1.0%

Filings

Newest first, from SEC EDGAR

Sources and methodology

Data on this tab
SEC EDGAR and our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.